Metabolomics-Based Elucidation of Therapeutic Mechanism of Luteolin Towards Autism in Children and Relevant Drug-Drug Interaction Risk

被引：0
|
作者：
Sun, Xingzhen [1 ]
Li, Chaoyang [1 ]
Wang, Xiang [1 ]
Zhang, Rongrong [1 ]
Hong, Ze [1 ]
机构：
[1] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Gen Pediat, Huaian 223300, Jiangsu, Peoples R China
来源：
LATIN AMERICAN JOURNAL OF PHARMACY | 2015年 / 34卷 / 03期
关键词：
autism; drug safety; lutrolin; metabolomics; SPECTRUM DISORDERS; FORMULATION;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Limited understanding for pathogenetic autism spectrum disorders results in the limited drugs for these diseases. In the present study, metabolomics-based analysis method was employed to compare healthy volunteers (n = 10), autism children (n = 10), and luteolin-treated autism children (n = 10). The results showed that autism children exhibited higher long-chain fatty acid-carnitine conjugates than healthy volunteers, indicating the inhibition of fatty acids oxidative process in autism children. The treatment with luteolin significantly decreased the level of long-chain fatty acid-carnitine conjugates. The drug-drug interaction risk between luteolin and zidovudine was furtherly determined, and the results showed that luteolin did not affect the metabolism of these two drugs. In conclusion, metabolomics-based analysis of luteolin-treated autism patients showed that luteolin can reverse autism-induced inhibition of fatty acids metabolism. Additionally, this drug is relatively safe because of none of drug-drug interaction.
引用
收藏
页码：590 / 592
页数：3
相关论文
共 50 条
  • [41] Machine-learning based drug-drug interaction prediction identifies acetylsalicylic acid as risk for cardiovascular events during migraine treatment
    Gecse, Kinga
    Duc Anh Nguyen
    Juhasz, Gabriella
    Mamitsuka, Hiroshi
    Petschner, Peter
    CEPHALALGIA, 2023, 43 (1supp) : 76 - 76
  • [42] Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management
    Zhou, Yi-Ting
    Yu, Lu-Shan
    Zeng, Su
    Huang, Yu-Wen
    Xu, Hui-Min
    Zhou, Quan
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 17 - 25
  • [43] Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development
    Cleary, Yumi
    Gertz, Michael
    Morcos, Peter N.
    Yu, Li
    Youdim, Kuresh
    Phipps, Alex
    Fowler, Stephen
    Parrott, Neil
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (03) : 505 - 514
  • [44] Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8
    Takagi, Motoi
    Sakamoto, Masaya
    Itoh, Tomoo
    Fujiwara, Ryoichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 288 - 294
  • [45] An automated in vitro screening system to assess risk of drug-drug interaction caused by metabolism-based inhibition of CYP3A4
    Watanabe, Akiko
    Nakamura, Koichi
    Okudaira, Noriko
    Okazaki, Osamu
    Sudo, Ken-ichi
    DRUG METABOLISM REVIEWS, 2006, 38 : 99 - 100
  • [46] Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information
    Kim, Soo-Jin
    Yoshikado, Takashi
    Ieiri, Ichiro
    Maeda, Kazuya
    Kimura, Miyuki
    Irie, Shin
    Kusuhara, Hiroyuki
    Sugiyama, Yuichi
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (10) : 1622 - 1632
  • [47] Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective
    Li, Chunze
    Menon, Rajeev
    Walles, Markus
    Singh, Renu
    Upreti, Vijay V.
    Brackman, Deanna
    Lee, Anthony J.
    Endres, Christopher J.
    Kumar, Seema
    Zhang, Donglu
    Barletta, Frank
    Suri, Ajit
    Hainzl, Dominik
    Liao, Kai H.
    Lalovic, Bojan
    Beaumont, Maribel
    Zuo, Peiying
    Mayer, Andrew P.
    Wei, Dong
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (04) : 754 - 769
  • [48] Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods
    Grime, Kenneth H.
    Bird, James
    Ferguson, Douglas
    Riley, Robert J.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 36 (2-3) : 175 - 191
  • [49] Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process
    Watanabe, Akiko
    Nakamura, Koichi
    Okudaira, Noriko
    Okazaki, Osamu
    Sudo, Ken-ichi
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (07) : 1232 - 1238
  • [50] Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats
    Kanazu, Takushi
    Sato, Norihito
    Kadono, Kyoko
    Touchi, Akira
    Takeda, Yuri
    Yamaguchi, Yoshitaka
    Baba, Takahiko
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (04) : 195 - 206
12345